Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
  • Merck And Company accounts for 4.85 % of our USA Portfolio. A trade is currently open since 10/23/2019 with a purchase price of $ 81.71. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The stock is in a well-established, long-term rising trend above the technical support level at 79.73 USD
Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • Based on current prices, the company has particularly high valuation levels.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK AND COMPANY9.40%211 953
JOHNSON & JOHNSON3.06%344 670
ROCHE HOLDING AG22.19%254 722
PFIZER-15.12%208 023
NOVARTIS17.78%198 320
NOVO NORDISK AS30.58%133 015
AMGEN13.58%128 581
ASTRAZENECA23.91%123 868
ABBVIE-7.57%121 382
SANOFI9.70%115 521
GLAXOSMITHKLINE16.48%109 685
ELI LILLY AND COMPANY-1.89%109 282
BRISTOL-MYERS SQUIBB COMPAN..11.62%92 804
CELGENE CORPORATION70.92%77 036
BAYER AG16.63%74 044
TAKEDA PHARMACEUTICAL COMPA..20.94%60 381
More Results
Financials (USD)
Sales 2019 46 501 M
EBIT 2019 16 340 M
Net income 2019 10 062 M
Debt 2019 20 089 M
Yield 2019 2,67%
P/E ratio 2019 21,5x
P/E ratio 2020 16,7x
EV / Sales2019 4,99x
EV / Sales2020 4,65x
Capitalization 212 B
Upcoming event on MERCK AND COMPANY
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes